- Report
- October 2024
- 183 Pages
Global
From €3230EUR$3,545USD£2,805GBP
€3589EUR$3,939USD£3,116GBP
- Report
- October 2024
- 183 Pages
Global
From €3230EUR$3,545USD£2,805GBP
€3589EUR$3,939USD£3,116GBP
- Report
- October 2024
- 199 Pages
Global
From €3230EUR$3,545USD£2,805GBP
€3589EUR$3,939USD£3,116GBP
- Report
- October 2024
- 193 Pages
Global
From €3230EUR$3,545USD£2,805GBP
€3589EUR$3,939USD£3,116GBP
- Report
- October 2024
- 183 Pages
Global
From €3230EUR$3,545USD£2,805GBP
€3589EUR$3,939USD£3,116GBP
- Report
- October 2024
- 199 Pages
Global
From €3230EUR$3,545USD£2,805GBP
€3589EUR$3,939USD£3,116GBP
- Report
- October 2024
- 190 Pages
Global
From €3230EUR$3,545USD£2,805GBP
€3589EUR$3,939USD£3,116GBP
- Report
- October 2024
- 194 Pages
Global
From €3230EUR$3,545USD£2,805GBP
€3589EUR$3,939USD£3,116GBP
- Report
- October 2024
- 195 Pages
Global
From €3230EUR$3,545USD£2,805GBP
€3589EUR$3,939USD£3,116GBP
- Report
- October 2024
- 182 Pages
Global
From €3230EUR$3,545USD£2,805GBP
€3589EUR$3,939USD£3,116GBP
- Report
- October 2024
- 185 Pages
Global
From €3230EUR$3,545USD£2,805GBP
€3589EUR$3,939USD£3,116GBP
- Report
- October 2024
- 195 Pages
Global
From €3230EUR$3,545USD£2,805GBP
€3589EUR$3,939USD£3,116GBP
- Report
- March 2025
- 188 Pages
Global
From €3230EUR$3,545USD£2,805GBP
€3589EUR$3,939USD£3,116GBP
- Report
- October 2024
- 188 Pages
Global
From €3230EUR$3,545USD£2,805GBP
€3589EUR$3,939USD£3,116GBP
- Report
- October 2024
- 184 Pages
Global
From €3230EUR$3,545USD£2,805GBP
€3589EUR$3,939USD£3,116GBP
- Report
- October 2024
- 196 Pages
Global
From €3230EUR$3,545USD£2,805GBP
€3589EUR$3,939USD£3,116GBP
- Report
- October 2024
- 188 Pages
Global
From €3230EUR$3,545USD£2,805GBP
€3589EUR$3,939USD£3,116GBP
- Report
- October 2024
- 194 Pages
Global
From €3230EUR$3,545USD£2,805GBP
€3589EUR$3,939USD£3,116GBP
- Report
- October 2024
- 196 Pages
Global
From €3230EUR$3,545USD£2,805GBP
€3589EUR$3,939USD£3,116GBP
- Report
- October 2024
- 191 Pages
Global
From €3230EUR$3,545USD£2,805GBP
€3589EUR$3,939USD£3,116GBP

Glaucoma is a group of eye diseases that damage the optic nerve, leading to vision loss. It is the leading cause of irreversible blindness worldwide. The glaucoma market within the optical industry is focused on providing treatments and technologies to diagnose and manage the disease. This includes medications, laser treatments, and surgical procedures. Additionally, the market includes devices such as tonometers, optical coherence tomography (OCT) systems, and visual field analyzers. These devices are used to measure intraocular pressure, detect structural changes in the eye, and assess the extent of vision loss.
Companies in the glaucoma market include Allergan, Bausch + Lomb, Carl Zeiss Meditec, Ellex, Glaukos, Hoya, Nidek, Topcon, and Ziemer Ophthalmic Systems. Show Less Read more